Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8U3Q2)

Drug Name

BAY-1075553 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DM8U3Q2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glutamate carboxypeptidase II (GCPII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capromab	DMHERIJ	Prostate cancer	2C82.0	Approved	[3]
PSMA-11 Ga-68	DMWLTU2	Diagnostic imaging	N.A.	Approved	[4]
Lutetium Lu-177 vipivotide tetraxetan	DMQ0IZ6	Prostate cancer	2C82.0	Approved	[5]
177-Lu-PSMA-617	DMX178V	Prostate cancer	2C82.0	Phase 3	[6]
BAY 2315497	DMUHH2G	Prostate cancer	2C82.0	Phase 3	[7]
J 591 Lu-177	DM9XKJU	Prostate cancer	2C82.0	Phase 2	[8]
G-202	DMQR9I8	Adenocarcinoma	2D40	Phase 2	[9]
ATL101	DMYAQV2	Influenza virus infection	1E30-1E32	Phase 2	[10]
99mTc-MIP-1404	DML4GU1	Prostate cancer	2C82.0	Phase 2	[11]
MLN-591RL	DMJHVZC	Prostate cancer	2C82.0	Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate carboxypeptidase II (GCPII)	TT9G4N0	FOLH1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Phase I Study: BAY 1075553 PET/CT in Staging and Re - Staging of Prostate Cancer Patients - Comparison with 18F-Choline PET/CT. World Molecular Imaging Society. September 20, 2013
2	Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):89-101.
3	Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5	[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
6	Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921.
7	ClinicalTrials.gov (NCT03724747) Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
8	Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
9	National Cancer Institute Drug Dictionary (drug id 666090).
10	Clinical pipeline report, company report or official report of Atlab pharma.
11	99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
12	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28.